Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019

Iwona Gorczyca-Głowacka, Bernadetta Bielecka, Paweł Wałek, Magdalena Chrapek, Agnieszka Ciba-Stemplewska, Olga Jelonek, Anna Kot, Anna Czyżyk, Maciej Pióro, Agnieszka Major and Beata Wożakowska-Kapłon
Additional contact information
Iwona Gorczyca-Głowacka: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
Bernadetta Bielecka: 1st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Centre, 25-736 Kielce, Poland
Paweł Wałek: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
Magdalena Chrapek: Faculty of Natural Sciences, Jan Kochanowski University, 25-369 Kielce, Poland
Agnieszka Ciba-Stemplewska: Department of Internal Medicine, Integrated Provincial Hospital, 25-736 Kielce, Poland
Olga Jelonek: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
Anna Kot: 1st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Centre, 25-736 Kielce, Poland
Anna Czyżyk: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
Maciej Pióro: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
Agnieszka Major: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland
Beata Wożakowska-Kapłon: Collegium Medicum, Jan Kochanowski University, 25-369 Kielce, Poland

IJERPH, 2022, vol. 19, issue 9, 1-11

Abstract: Background: In the recent years, antithrombotic prophylaxis in patients with atrial fibrillation (AF) has changed significantly. The main aim of this study is to assess the temporal trends of antithrombotic therapy and identify factors predisposing oral anticoagulant (OAC) use in stroke prevention in AF patients. Methods: The present study is a retrospective, observational, single-center study, which includes consecutively hospitalized patients in the reference cardiology center from January 2004 to December 2019. Results: A total of 9656 patients (43.7% female, mean age 71.2 years) with AF between 2004–2019 are included. Among the total study population, in most of the patients (81.1%), OAC therapy was used, antiplatelet (APT) therapy was prescribed for 13.5% patients, heparins for 2.1% patients and 3.3% of patients did not receive any stroke prevention. OAC prescription significantly increased from 61.6% in 2004 to 97.4% in 2019. The independent predictors of OAC prescription were: the period of hospitalization, non-paroxysmal AF, age, hypertension, diabetes mellitus, previous thromboembolism, hospitalization due to electrical cardioversion, ablation or AF without any procedures. Conclusions: In hospitalized patients with AF, during sixteen years of the study period, a significant increase in OAC use and a decrease in APT use were noted. Factors other than these included in the CHA 2 DS 2 -VASc score were independent predictors of OAC use.

Keywords: atrial fibrillation; non-vitamin K antagonist oral anticoagulants; oral anticoagulants; vitamin K antagonists (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/9/5584/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/9/5584/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:9:p:5584-:d:808431

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().